Neuronetics, Inc. (STIM)

4.2400

+0.0500

+(1.19%)

At close: April 24 at 4:00:00 PM EDT

4.2500

+0.01

+(0.24%)

After hours: April 24 at 7:46:43 PM EDT

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conferen

GlobeNewswire 2 days ago

STIM
+1.19%
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expande

GlobeNewswire 24 days ago

STIM
+1.19%
Neuronetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Neuronetics ( NASDAQ:STIM ) Full Year 2024 Results Key Financial Results Revenue: US$74.9m (up 5.0% from FY 2023). Net...

Simply Wall St. 25 days ago

STIM
+1.19%
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company’s press release on March 4, 2025 initially issuing the Company’s fourth quarter and full year 2024 financial results (the “Initial Release”) and in connection with finalizing the audited financial statements for the fisca

GlobeNewswire 28 days ago

STIM
+1.19%
While private equity firms own 38% of Neuronetics, Inc. (NASDAQ:STIM), retail investors are its largest shareholders with 43% ownership

Key Insights Neuronetics' significant retail investors ownership suggests that the key decisions are influenced by...

Simply Wall St. last month

STIM
+1.19%
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet

The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

STIM
+1.19%
Neuronetics Inc (STIM) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Rising Expenses ...

Neuronetics Inc (STIM) reports an 11% revenue increase, driven by strategic acquisitions and market expansion, despite challenges in gross margin and operating expenses.

GuruFocus.com last month

STIM
+1.19%
^YH206
Q4 2024 Neuronetics Inc Earnings Call

Q4 2024 Neuronetics Inc Earnings Call

Thomson Reuters StreetEvents last month

STIM
+1.19%
^YH206
Neuronetics: Q4 Earnings Snapshot

STIM) on Tuesday reported a loss of $12.2 million in its fourth quarter. On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 33 cents. The medical device company focused on psychiatric disorders posted revenue of $22.5 million in the period.

Associated Press Finance last month

STIM
+1.19%
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Acquired Greenbroo

GlobeNewswire last month

STIM
+1.19%
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company’s common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5

GlobeNewswire last month

STIM
+1.19%
Neuronetics, Inc. (STIM): Among the Hot Penny Stocks to Buy Now

We recently compiled a list of the 10 Hot Penny Stocks to Buy Now. In this article, we are going to take a look at where Neuronetics, Inc. (NASDAQ:STIM) stands against the other hot penny stocks. How Did Small Caps Do In Q4 2024? On January 2, Royce Investment Partners published their analysis regarding the performance […]

Insider Monkey last month

STIM
+1.19%
^RUT
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The confer

GlobeNewswire 2 months ago

STIM
+1.19%
News Flash: Analysts Just Made A Stunning Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Forecasts

Neuronetics, Inc. ( NASDAQ:STIM ) shareholders will have a reason to smile today, with the analysts making substantial...

Simply Wall St. 2 months ago

STIM
+1.19%
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company has also granted to th

GlobeNewswire 2 months ago

STIM
+1.19%
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All shares in the offering are being offered by the Company. Canaccord Genuity LLC is acting as sole bookrunner in conne

GlobeNewswire 2 months ago

STIM
+1.19%
Why Neuronetics Inc (STIM) Is Skyrocketing So Far In 2025

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Neuronetics Inc (NASDAQ:STIM) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These […]

Insider Monkey 2 months ago

STIM
+1.19%
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression

Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical toolsMALVERN, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two peer-reviewed publications in the inaugural edition of the Transcranial Magnetic Stimulation journal. The first

GlobeNewswire 2 months ago

STIM
+1.19%
Neuronetics (NASDAQ:STIM) shareholders are up 34% this past week, but still in the red over the last five years

It is a pleasure to report that the Neuronetics, Inc. ( NASDAQ:STIM ) is up 181% in the last quarter. But that doesn't...

Simply Wall St. 2 months ago

STIM
+1.19%
Neuronetics Provides Business Update and Issues 2025 Guidance

Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9, 2024Expects full year 2025 pro forma year-over-year revenue growth of 12% - 19%Expects to realize over $22 million in annualized cost synergies Expects to achieve cash flow breakeven in the third quarter of 2025 MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced preliminary f

GlobeNewswire 3 months ago

STIM
+1.19%

Performance Overview

Return	STIM	S&P 500 (^GSPC)
YTD	+163.35%	-6.75%
1-Year	+13.07%	+8.15%
3-Year	+48.77%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Survey

Neuronetics, Inc. (STIM)

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

Neuronetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

While private equity firms own 38% of Neuronetics, Inc. (NASDAQ:STIM), retail investors are its largest shareholders with 43% ownership

Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet

Neuronetics Inc (STIM) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Rising Expenses ...

Q4 2024 Neuronetics Inc Earnings Call

Neuronetics: Q4 Earnings Snapshot

Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc. (STIM): Among the Hot Penny Stocks to Buy Now

Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

News Flash: Analysts Just Made A Stunning Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Forecasts

Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

Why Neuronetics Inc (STIM) Is Skyrocketing So Far In 2025

NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression

Neuronetics (NASDAQ:STIM) shareholders are up 34% this past week, but still in the red over the last five years

Neuronetics Provides Business Update and Issues 2025 Guidance

Performance Overview